SEC Comment Letter 0000000000-24-012220 to DataMeds AI, Inc. (WGRX)
DataMeds AI, Inc.
Date: Nov. 4, 2024 · CIK: 0002030763 · Accession: 0000000000-24-012220
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-280945
Letter
November 4, 2024 Tim Canning Chief Executive Officer Wellgistics Health, Inc. 3000 Bayport Drive Suite 950 Tampa, FL 33607 Re:Wellgistics Health, Inc. Amendment No. 3 to Registration Statement on Form S-1 Filed October 21, 2024 File No. 333-280945 Dear Tim Canning: We have reviewed your amended registration statement and have the following comment(s). Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe a comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to this letter, we may have additional comments. Amendment No. 3 to Registration Statement on Form S-1 Capitalization, page 44 1.Please explain why there are differences in cash and accumulated deficit amounts in the Pro Forma column as compared to page 49. Danam Health, Inc. Statement of Operations, page F-4 2.Please provide us your calculation of net loss per common share.
November 4, 2024 Page 2 Community Specialty Pharmacy, LLC Independent Auditors' Report, page F-95 3.Please have your auditor specify the period(s) covered by each financial statement identified in the report and the period(s) to which the opinion applies. Refer to paragraph 8c of AS 3101. Alliance Pharmaceutical Solutions, LLC Independent Auditors' Report, page F-113 4.Please have your auditor specify the period(s) covered by each financial statement identified in the report and the period(s) to which the opinion applies. Refer to paragraph 8c of AS 3101. Please contact Tony Watson at 202-551-3318 or Lyn Shenk at 202-551-3380 with any questions. Sincerely, Division of Corporation Finance Office of Trade & Services cc:Kate Bechen
Show Raw Text
November 4, 2024
Tim Canning
Chief Executive Officer
Wellgistics Health, Inc.
3000 Bayport Drive
Suite 950
Tampa, FL 33607
Re:Wellgistics Health, Inc.
Amendment No. 3 to Registration Statement on Form S-1
Filed October 21, 2024
File No. 333-280945
Dear Tim Canning:
We have reviewed your amended registration statement and have the following
comment(s).
Please respond to this letter by amending your registration statement and providing
the requested information. If you do not believe a comment applies to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your registration statement and the information
you provide in response to this letter, we may have additional comments.
Amendment No. 3 to Registration Statement on Form S-1
Capitalization, page 44
1.Please explain why there are differences in cash and accumulated deficit amounts in
the Pro Forma column as compared to page 49.
Danam Health, Inc.
Statement of Operations, page F-4
2.Please provide us your calculation of net loss per common share.
November 4, 2024
Page 2
Community Specialty Pharmacy, LLC
Independent Auditors' Report, page F-95
3.Please have your auditor specify the period(s) covered by each financial statement
identified in the report and the period(s) to which the opinion applies. Refer
to paragraph 8c of AS 3101.
Alliance Pharmaceutical Solutions, LLC
Independent Auditors' Report, page F-113
4.Please have your auditor specify the period(s) covered by each financial statement
identified in the report and the period(s) to which the opinion applies. Refer
to paragraph 8c of AS 3101.
Please contact Tony Watson at 202-551-3318 or Lyn Shenk at 202-551-3380 with any
questions.
Sincerely,
Division of Corporation Finance
Office of Trade & Services
cc:Kate Bechen